Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05194579 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT05194579 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 141 participants.
The verdict
NCT05194579, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
This will be an open-label, randomized, 2-treatment, 2-period, crossover single-dose study in approximately 134 healthy adult participants. Participants will be randomized into 2 sequences of treatment as described in the following table of Intervention Groups and Duration.
Interventions
- COMBINATION_PRODUCT PF-06881894 by on-body injector
- COMBINATION_PRODUCT PF-06881894 by prefilled syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05194579
The ClinicalTrials.gov registry entry for NCT05194579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06881894 by on-body injector is the first listed.
NCT05194579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05194579 about?
NCT05194579 is a clinical study titled "Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe". This will be an open-label, randomized, 2-treatment, 2-period, crossover single-dose study in approximately 134 healthy adult participants. Participants will be randomized into 2 sequences of treatment as described in the following table of Intervention Groups and Duration.
What is the current status of trial NCT05194579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2022-02-10. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT05194579?
The interventions under investigation include: PF-06881894 by on-body injector (COMBINATION_PRODUCT), PF-06881894 by prefilled syringe (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05194579?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.